Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.44 Insider Own15.72% Shs Outstand44.12M Perf Week9.61%
Market Cap135.89M Forward P/E- EPS next Y-1.14 Insider Trans0.00% Shs Float37.18M Perf Month18.92%
Income-19.27M PEG- EPS next Q- Inst Own12.15% Short Float0.01% Perf Quarter18.01%
Sales18.13M P/S7.50 EPS this Y-113.33% Inst Trans-19.65% Short Ratio0.08 Perf Half Y108.11%
Book/sh1.60 P/B1.93 EPS next Y-52.68% ROA-14.37% Short Interest0.00M Perf Year123.19%
Cash/sh2.49 P/C1.24 EPS next 5Y- ROE-25.08% 52W Range1.10 - 4.38 Perf YTD59.47%
Dividend Est.- P/FCF- EPS past 5Y-5.97% ROI-22.86% 52W High-29.68% Beta0.66
Dividend TTM- Quick Ratio3.61 Sales past 5Y283.15% Gross Margin- 52W Low179.97% ATR (14)0.23
Dividend Ex-Date- Current Ratio3.61 EPS Y/Y TTM76.56% Oper. Margin-152.27% RSI (14)60.59 Volatility11.20% 8.71%
Employees174 Debt/Eq0.32 Sales Y/Y TTM91.01% Profit Margin-106.27% Recom1.00 Target Price6.00
Option/ShortNo / Yes LT Debt/Eq0.19 EPS Q/Q- Payout- Rel Volume0.40 Prev Close3.10
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMar 29 BMO Avg Volume33.09K Price3.08
SMA2011.86% SMA5018.37% SMA20033.21% Trades Volume13,394 Change-0.65%
Date Action Analyst Rating Change Price Target Change
Jun-25-21Initiated China Renaissance Buy $40.57
Mar-08-21Initiated Morgan Stanley Overweight $34
Mar-08-21Initiated Jefferies Buy $33
Mar-08-21Initiated Goldman Buy $29
May-22-24 04:45PM
Mar-29-24 09:00AM
Mar-07-24 04:01PM
Feb-27-24 08:00AM
Feb-09-24 06:00AM
07:00AM Loading…
Jan-17-24 07:00AM
Jan-16-24 05:01PM
Jan-04-24 05:00AM
Nov-03-23 12:00PM
Oct-30-23 09:40AM
Oct-13-23 09:40AM
Oct-12-23 08:00AM
Sep-27-23 09:40AM
Sep-07-23 10:45PM
07:32AM Loading…
Aug-31-23 07:32AM
May-25-23 09:40AM
May-04-23 09:00AM
Apr-28-23 07:00AM
Apr-18-23 09:17AM
Mar-31-23 09:40AM
Mar-28-23 04:30PM
Mar-14-23 06:00PM
Mar-05-23 07:39PM
Jan-09-23 07:00AM
Jan-05-23 04:01PM
Dec-16-22 06:30AM
Nov-21-22 04:05PM
Nov-10-22 09:05AM
04:03PM Loading…
Oct-11-22 04:03PM
Sep-10-22 04:13AM
Aug-30-22 05:25PM
Jun-29-22 04:05PM
May-26-22 09:30PM
May-12-22 07:00AM
May-02-22 06:06AM
Apr-08-22 01:09PM
Apr-03-22 02:34PM
Mar-31-22 08:30AM
Mar-17-22 10:42AM
Mar-16-22 10:00AM
Mar-08-22 09:21PM
Mar-02-22 08:22AM
Feb-08-22 07:00AM
Feb-02-22 04:05PM
Jan-27-22 07:00AM
Jan-19-22 07:00AM
Jan-13-22 04:00AM
Dec-22-21 04:05PM
Dec-13-21 10:23AM
Dec-06-21 01:49PM
Nov-30-21 04:01PM
Nov-29-21 04:05PM
Nov-22-21 05:05PM
Nov-09-21 04:05PM
Nov-04-21 09:24AM
Oct-27-21 08:52AM
Oct-21-21 08:00AM
Sep-17-21 12:22PM
Sep-02-21 07:45AM
Aug-26-21 07:45AM
Aug-19-21 07:37AM
Aug-12-21 07:45AM
Jul-22-21 07:45AM
Jul-12-21 10:15PM
Jul-09-21 10:47AM
Jul-07-21 07:45AM
Jun-16-21 04:49PM
May-25-21 04:05PM
May-19-21 05:05PM
Apr-13-21 07:45AM
Mar-31-21 07:45AM
Mar-29-21 07:45AM
Mar-16-21 08:05AM
Feb-11-21 10:08AM
Feb-09-21 05:18PM
Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.